Shots:
- Italfarmaco & JCR Pharmaceuticals have entered an exclusive license agreement to develop & potentially commercialize JR-141 (pabinafusp alfa) in the US, Europe, & Latin America for Hunter syndrome (MPS II)
- The companies seek approvals for JR-141 in the US, EU, UK & Brazil. Following approval, Italfarmaco will commercialize & distribute JR-141 in licensed territories, while JCR will retain manufacturing responsibility & receive upfront, milestone & royalty payments plus product-supply revenues
- JR-141 is a P-III, BBB-penetrating enzyme replacement therapy that uses JCR’s J-Brain Cargo technology to deliver iduronate-2-sulfatase across the BBB, targeting both somatic & neuronopathic symptoms
Ref: Businesswire | Image: Italfarmaco & JCR | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
